[CBC News] Samchundang Pharmaceutical extended its gains during the March 27 session, trading in the 170,000-won range. With recent price volatility widening, the stock is showing strength for a second consecutive day following the previous session's rise.

As of the afternoon on the 27th, Samchundang Pharm was trading at 172,700 won, up 1,600 won (0.94%) from the previous trading day, with intraday volume reaching 113,347 shares. The previous day, the 26th, it closed at 169,800 won, up 0.12%.

However, viewed broadly, recent price movements have shown considerable volatility. On the 21st, the stock fell to as low as 169,100 won, down 7.49%, while it closed at 182,900 won on the 20th (up 1.84%), 180,500 won on the 19th (down 2.22%), and 183,600 won on the 18th (down 3.17%). Considering that the stock finished trading at 191,200 won on the 13th and 189,500 won on the 14th, the recent trend can be seen as a partial recovery attempt after the share price slid from the 190,000-won range to the 160,000-won range.

In particular, given that gains and losses have alternated across recent trading days, rather than concluding a trend reversal based on a short-term rebound alone, further confirmation of direction in the 170,000-won range is needed.

Due to the characteristics of the biotech sector, Samchundang Pharm's stock price volatility can expand depending on R&D results, contract progress, and clinical and regulatory approval news. Beyond individual catalysts, overall investment sentiment in biotech stocks and changes in supply and demand can also affect the share price in the short term.

[Stock prices can exhibit heightened volatility depending on corporate performance, industry conditions, merger terms, market supply and demand, and other factors. Securities firms' analyses and forecasts may differ from actual future results and do not guarantee returns on any specific stock. Before making investment decisions, investors should comprehensively review the company's official disclosures, financial condition, and business progress. This article is not intended to recommend the purchase or sale of any specific stock. This article was written with AI assistance.]